HOTH Stock Price, Hoth Therapeutics Inc Quote, Chart

Market Summary

1.18-0.01

Market Closed

-0.84%

HOTH Stock Price

View Fullscreen

HOTH RSI Chart

HOTH Valuation

Market Cap

5.8M

Price/Earnings (Trailing)

-0.75

Price/Sales (Trailing)

2.84

Price/Free Cashflow

-0.73

HOTH Price/Sales (Trailing)

HOTH Profitability

Return on Equity

-98.34%

Return on Assets

-90.71%

Free Cashflow Yield

-136.63%

HOTH Fundamentals

HOTH Revenue

Revenue (TTM)

2.0M

Rev. Growth (Qtr)

12.58%

HOTH Earnings

Earnings (TTM)

-7.7M

Earnings Growth (Yr)

6.54%

Earnings Growth (Qtr)

-19.89%

Breaking Down HOTH Revenue

Last 7 days

0.9%

Last 30 days

-4.1%

Last 90 days

-14.5%

Trailing 12 Months

-24.8%

How does HOTH drawdown profile look like?

HOTH Financial Health

Current Ratio

13.14

HOTH Investor Care

Shares Dilution (1Y)

48.05%

Diluted EPS (TTM)

-1.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	2.5M	2.2M	2.0M	0
2021	2.5M	2.4M	2.3M	0
2020	2.6M	2.8M	2.8M	2.5M
2019	784.2K	1.1M	1.6M	2.1M
2018	0	0	0	682.9K
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Hoth Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 13, 2022	pavell jeff	acquired	-	-	5,075	-
Sep 19, 2022	knie robb	bought	3,900	0.39	10,000	ceo and president
Sep 16, 2022	knie robb	bought	4,000	0.4	10,000	ceo and president
May 26, 2020	hayes anthony	sold	-	-	-	-
May 26, 2020	hayes anthony	sold	-500,000	1.25	-400,000	-
May 26, 2020	aikido pharma inc.	sold	-500,000	1.25	-400,000	-
May 18, 2020	knie robb	acquired	-	-	4.00	ceo and president
Apr 15, 2020	linsley wayne	acquired	-	-	3,333	-
Apr 15, 2020	springer graig	acquired	-	-	3,333	-
Nov 08, 2019	hayes anthony	sold	-	-	-9,226	-

Which funds bought or sold HOTH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	623,200	623,200	0.01%
May 15, 2024	Tower Research Capital LLC (TRC)	added	301	7,257	9,500	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	MORGAN STANLEY	added	166,700	15,205	15,213	-%
May 14, 2024	Qube Research & Technologies Ltd	new	-	456	456	-%
May 14, 2024	Farther Finance Advisors, LLC	sold off	-100	-1.00	-	-%
May 13, 2024	UBS Group AG	reduced	-74.55	-8,896	3,268	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	8.77	5,014	38,855	-%
May 10, 2024	JPMORGAN CHASE & CO	sold off	-100	-9,125	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	13.33	9.00	52.00	-%

Are Funds Buying or Selling HOTH?

Are funds buying HOTH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HOTH

No. of Funds

Unveiling Hoth Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	228,278	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	144,518	SC 13G
Feb 08, 2023	intracoastal capital, llc	4.2%	57,008	SC 13G/A
Feb 23, 2022	iroquois capital management, llc	3.66%	911,392	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	5.6%	1,425,200	SC 13G/A
Feb 09, 2022	lind global macro fund lp	3.2%	792,287	SC 13G/A
Feb 03, 2022	ionic ventures, llc	1.72%	412,542	SC 13G/A
Mar 18, 2021	iroquois capital management, llc	4.0%	911,392	SC 13G
Feb 17, 2021	aikido pharma inc.	9.74%	0	SC 13G
Feb 16, 2021	eitner matthew d.	0.14%	18,750	SC 13G/A

Recent SEC filings of Hoth Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
Apr 22, 2024	424B3	Prospectus Filed
Apr 19, 2024	EFFECT	EFFECT
Apr 18, 2024	CORRESP	CORRESP
Apr 17, 2024	UPLOAD	UPLOAD
Apr 11, 2024	S-1	Initial Public Offering
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	424B3	Prospectus Filed
Mar 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Hoth Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Hoth Therapeutics Inc News

Latest updates

Hoth Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	12.6%	616	547	479	484	616	557	498	524	487	520	700	801	302	621	750	806	610	643	545	294	153
Operating Expenses	21.0%	2,054	1,698	2,093	1,709	2,193	3,421	2,684	2,300	2,661	3,253	3,199	4,269	803	2,167	2,516	1,816	3,918	1,700	1,268	829	584
S&GA Expenses	-	-	-	-	-	-	-	-	238	-	-	219	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-33.7%	466	702	1,246	641	891	1,560	1,451	971	948	2,124	1,752	1,533	189	518	928	647	1,011	490	389	135	228
Net Income	-19.9%	-2,040	-1,702	-2,086	-1,873	-2,183	-3,478	-2,644	-2,677	-2,571	-3,296	-3,275	-4,261	-756	-2,116	-2,497	-1,826	-3,911	-1,696	-1,267	-829	-584
Net Income Margin	1.8%	-3.80*	-3.87*	-4.74*	-5.02*	-5.42*	-5.61*	-5.61*	-5.39*	-5.03*	-4.99*	-4.30*	-3.89*	-	-	-	-	-	-	-	-	-
Free Cashflow	43.9%	-1,723	-3,071	-1,636	-1,449	-2,289	-2,550	-2,388	-2,222	-2,136	-2,702	-2,762	-2,722	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.8%	8,491	9,520	12,086	11,917	13,462	6,759	9,895	12,250	8,945	10,985	15,188	18,029	20,992	5,243	5,950	7,426	5,348	2,836	4,335	4,428	5,456
Current Assets	-10.8%	8,406	9,428	12,053	11,884	13,429	6,726	9,507	11,863	8,535	10,575	14,778	17,569	20,532	4,783	5,490	7,016	4,897	2,635	4,133	4,226	5,254
Cash Equivalents	-18.6%	7,563	9,292	11,828	11,545	13,044	6,429	8,935	11,318	6,381	8,538	12,445	15,851	19,302	2,630	4,121	4,947	4,549	1,891	3,415	4,293	5,366
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	124*	433*	738*	1.00	1.00	2.00	2.00
Liabilities	-6.6%	659	705	1,579	1,966	1,596	1,638	1,283	1,029	1,061	1,103	1,842	1,454	1,044	597	573	590	523	440	340	239	88.00
Current Liabilities	-5.7%	640	679	1,579	1,716	1,346	1,388	1,008	754	826	868	1,607	1,219	759	312	288	355	523	440	25.00	239	88.00
Shareholder's Equity	-11.1%	7,833	8,815	10,507	9,951	11,866	5,122	8,611	11,222	7,884	9,882	13,346	16,575	19,948	4,646	5,377	6,836	4,824	2,396	4,309	4,188	5,368
Retained Earnings	-3.9%	-54,985	-52,944	-51,242	-49,155	-47,282	-45,099	-41,620	-38,976	-36,298	-33,727	-30,247	-26,951	-23,675	-19,413	-18,656	-16,539	-14,042	-12,215	-8,303	-6,607	-5,340
Additional Paid-In Capital	1.7%	62,796	61,732	61,726	59,130	59,120	50,199	50,182	50,167	44,167	43,592	43,571	43,523	43,630	24,073	24,036	23,375	18,865	14,611	12,612	10,795	10,708
Shares Outstanding	1.3%	4,404	4,348	4,346	3,302	3,302	1,302	1,164	1,101	959	959	871	948	707	-	-	-	-	-	-	-	-
Float	-	-	-	-	9,800	-	-	-	13,100	-	-	-	36,737	-	-	-	32,175	-	-	-	36,214	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	43.9%	-1,723	-3,071	-1,636	-1,449	-2,289	-2,550	-2,388	-2,222	-2,136	-3,902	-2,702	-2,762	-2,722	-657	-1,495	-2,397	-1,582	-1,499	-1,637	-1,046	-763
Share Based Compensation	8773.8%	513	6.00	190	10.00	11.00	15.00	12.00	16.00	577	143	24.00	30.00	1,126	37.00	693	-15.93	24.00	1,998	207	87.00	203
Cashflow From Investing	-	-	-	-	-	-	-7.50	10.00	1,184	-25.00	-17.48	-579	-525	957	-821	672	-1,697	10.00	-25.00	-850	-10.00	-10.00
Cashflow From Financing	-	-	-	2,406	-	8,911	51.00	-	-	-	-	-100	-136	18,431	-	-	4,494	4,231	-	1,610	-17.17	5,858

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HOTH Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
OPERATING COSTS AND EXPENSES:
Research and development expense	$ 465,896	$ 938,878
General and administrative expenses	1,588,262	1,253,939
Total operating expenses	2,054,158	2,192,817
LOSS FROM OPERATIONS	(2,054,158)	(2,192,817)
OTHER INCOME (EXPENSES), NET:
Unrealized loss on marketable securities		(18,803)
Change in fair value of investment in joint ventures	(581)
Dividend income	13,956	28,113
Total other income (expenses), net	13,375	9,310
NET LOSS	$ (2,040,783)	$ (2,183,507)
NET LOSS PER COMMON SHARE:
Net loss per share Basic (in Dollars per share)	$ (0.46)	$ (0.88)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
Weighted average number of common shares outstanding, basic (in Shares)	4,398,909	2,482,824
COMPREHENSIVE LOSS:
Net loss	$ (2,040,783)	$ (2,183,507)
Foreign currency translation adjustment	(5,768)	5,370
Total comprehensive loss	$ (2,046,551)	$ (2,178,137)

HOTH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 7,562,628	$ 9,292,352
Prepaid expenses and other current assets	293,160	135,361
Deferred offering cost	550,500
Total Current Assets	8,406,288	9,427,713
NON-CURRENT ASSETS:
Operating lease right-of-use asset, net	48,222	55,165
Investment in joint ventures at fair value	36,819	37,400
Total Non-current Assets	85,041	92,565
Total Assets	8,491,329	9,520,278
CURRENT LIABILITIES:
Accounts payable	360,905	35,592
Accrued expenses	249,608	614,226
Operating lease liability, current portion	29,321	28,839
Total Current Liabilities	639,834	678,657
LONG-TERM LIABILITIES:
Operating lease liability, less current portion	18,901	26,326
Total Long-Term Liabilities	18,901	26,326
Total Liabilities	658,735	704,983
Commitments and Contingencies (Note 6)
STOCKHOLDERS’ EQUITY:
Preferred stock, value
Common stock, $0.0001 par value; 50,000,000 shares authorized; 4,403,804 and 4,348,129 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	440	435
Additional paid-in capital	62,795,951	61,732,106
Accumulated deficit	(54,985,289)	(52,944,506)
Accumulated other comprehensive income	21,492	27,260
Total Stockholders’ Equity	7,832,594	8,815,295
Total Liabilities and Stockholders’ Equity	8,491,329	9,520,278
Series A Convertible Preferred Stock
STOCKHOLDERS’ EQUITY:
Preferred stock, value
Series B Preferred Stock
STOCKHOLDERS’ EQUITY:
Preferred stock, value

About Hoth Therapeutics Inc

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; ZylÃƒÂ¶ Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

CEO	Mr. Robb Knie
WEBSITE	hoththerapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	2

Hoth Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Hoth Therapeutics Inc? What does HOTH stand for in stocks?

HOTH is the stock ticker symbol of Hoth Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hoth Therapeutics Inc (HOTH)?

As of Fri May 17 2024, market cap of Hoth Therapeutics Inc is 5.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOTH stock?

You can check HOTH's fair value in chart for subscribers.

What is the fair value of HOTH stock?

You can check HOTH's fair value in chart for subscribers. The fair value of Hoth Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hoth Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HOTH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hoth Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HOTH is over valued or under valued. Whether Hoth Therapeutics Inc is cheap or expensive depends on the assumptions which impact Hoth Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOTH.

What is Hoth Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HOTH's PE ratio (Price to Earnings) is -0.75 and Price to Sales (PS) ratio is 2.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOTH PE ratio will change depending on the future growth rate expectations of investors.